Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses.


Journal

Nature biotechnology
ISSN: 1546-1696
Titre abrégé: Nat Biotechnol
Pays: United States
ID NLM: 9604648

Informations de publication

Date de publication:
25 Sep 2023
Historique:
received: 04 05 2022
accepted: 18 08 2023
pubmed: 26 9 2023
medline: 26 9 2023
entrez: 25 9 2023
Statut: aheadofprint

Résumé

Increasing evidence implicates the tumor microbiota as a factor that can influence cancer progression. In patients with colorectal cancer (CRC), we found that pre-resection antibiotics targeting anaerobic bacteria substantially improved disease-free survival by 25.5%. For mouse studies, we designed an antibiotic silver-tinidazole complex encapsulated in liposomes (LipoAgTNZ) to eliminate tumor-associated bacteria in the primary tumor and liver metastases without causing gut microbiome dysbiosis. Mouse CRC models colonized by tumor-promoting bacteria (Fusobacterium nucleatum spp.) or probiotics (Escherichia coli Nissle spp.) responded to LipoAgTNZ therapy, which enabled more than 70% long-term survival in two F. nucleatum-infected CRC models. The antibiotic treatment generated microbial neoantigens that elicited anti-tumor CD8

Identifiants

pubmed: 37749267
doi: 10.1038/s41587-023-01957-8
pii: 10.1038/s41587-023-01957-8
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK034987
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009512
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009512
Pays : United States

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.

Références

Bodinier, M. et al. Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding. Nat. Med. 6, 707–710 (2000).
pubmed: 10835691
Alard, E. et al. Advances in anti-cancer immunotherapy: CAR-T cell, checkpoint inhibitors, dendritic cell vaccines, and oncolytic viruses, and emerging cellular and molecular targets. Cancers (Basel) 12, 1826 (2020).
pubmed: 32645977
Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).
pubmed: 26028255 pmcid: 4481136
Nejman, D. et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science 368, 973–980 (2020).
pubmed: 32467386 pmcid: 7757858
Fluckiger, A. et al. Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage. Science 369, 936–942 (2020).
pubmed: 32820119
Kalaora, S. et al. Identification of bacteria-derived HLA-bound peptides in melanoma. Nature 592, 138–143 (2021).
pubmed: 33731925 pmcid: 9717498
Yang, Y. et al. Focused specificity of intestinal T
pubmed: 24739972 pmcid: 4128479
Zheng, D.-W. et al. Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy. Nat. Biomed. Eng. 3, 717–728 (2019).
pubmed: 31332342
Goodman, A. L. & Gordon, J. I. Our unindicted coconspirators: human metabolism from a microbial perspective. Cell Metab. 12, 111–116 (2010).
pubmed: 20674856 pmcid: 2935662
Kostic, A. D. et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 22, 292–298 (2012).
pubmed: 22009990 pmcid: 3266036
Sepich-Poore, G. D. et al. The microbiome and human cancer. Science 371, eabc4552 (2021).
pubmed: 33766858 pmcid: 8767999
Derosa, L. et al. Microbiota-centered interventions: the next breakthrough in immuno-oncology? Cancer Discov. 11, 2396–2412 (2021).
pubmed: 34400407
Song, M., Chan, A. T. & Sun, J. Influence of the gut microbiome, diet, and environment on risk of colorectal cancer. Gastroenterology 158, 322–340 (2020).
pubmed: 31586566
Poore, G. D. et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature 579, 567–574 (2020).
pubmed: 32214244 pmcid: 7500457
Rousseau, B. et al. Impact of antibiotics (ATB) on the recurrence of resected colorectal cancer (CRC): results of EVADER-1 a nation-wide pharmacoepidemiologic study. J. Clin. Oncol. 38, 4106 (2020).
Sargent, D. J. et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N. Engl. J. Med. 345, 1091–1097 (2001).
pubmed: 11596588
Castellarin, M. et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 22, 299–306 (2012).
pubmed: 22009989 pmcid: 3266037
Bullman, S. et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 358, 1443–1448 (2017).
pubmed: 29170280 pmcid: 5823247
Zhou, Z., Chen, J., Yao, H. & Hu, H. Fusobacterium and colorectal cancer. Front. Oncol. 8, 371 (2018).
pubmed: 30374420 pmcid: 6196248
Brennan, C. A. & Garrett, W. S. Fusobacterium nucleatum—symbiont, opportunist and oncobacterium. Nat. Rev. Microbiol. 17, 156–166 (2019).
pubmed: 30546113 pmcid: 6589823
Sun, Y. et al. Adaptive-guided-coupling-probability level set for retinal layer segmentation. IEEE J. Biomed. Health Inform. 24, 3236–3247 (2020).
pubmed: 32191901
Canale, F. P. et al. Metabolic modulation of tumours with engineered bacteria for immunotherapy. Nature 598, 662–666 (2021).
pubmed: 34616044
Wilson, M. R. et al. The human gut bacterial genotoxin colibactin alkylates DNA. Science 363, eaar7785 (2019).
Riquelme, E. et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell 178, 795–8062 (2019).
pubmed: 31398337 pmcid: 7288240
Ahn, J. et al. Human gut microbiome and risk for colorectal cancer. J. Natl Cancer Inst. 105, 1907–1911 (2013).
pubmed: 24316595 pmcid: 3866154
Pinato, D. J. et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 5, 1774–1778 (2019).
pubmed: 31513236 pmcid: 6743060
Arane, K. & Goldman, R. D. Fusobacterium infections in children. Can. Fam. Physician 62, 813–814 (2016).
pubmed: 27737977 pmcid: 5063768
Leitsch, D. et al. Pyruvate:ferredoxin oxidoreductase and thioredoxin reductase are involved in 5-nitroimidazole activation while flavin metabolism is linked to 5-nitroimidazole resistance in Giardia lamblia. J. Antimicrob. Chemother. 66, 1756–1765 (2011).
pubmed: 21602576 pmcid: 3133484
Upcroft, P. & Upcroft, J. A. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin. Microbiol. Rev. 14, 150–164 (2001).
pubmed: 11148007 pmcid: 88967
Dingsdag, S. A. & Hunter, N. Metronidazole: an update on metabolism, structure–cytotoxicity and resistance mechanisms. J. Antimicrob. Chemother. 73, 265–279 (2018).
pubmed: 29077920
Qiu, K., Durham, P. G. & Anselmo, A. C. Inorganic nanoparticles and the microbiome. Nano Res. 11, 4936–4954 (2018).
Kim, D. et al. Selective killing of pathogenic bacteria by antimicrobial silver nanoparticle–cell wall binding domain conjugates. ACS Appl. Mater. Interfaces 10, 13317–13324 (2018).
pubmed: 29619821
Prabhu, S. & Poulose, E. K. Silver nanoparticles: mechanism of antimicrobial action, synthesis, medical applications, and toxicity effects. Int. Nano Lett. 2, 32 (2012).
Waszczykowska, A., Żyro, D., Ochocki, J. & Jurowski, P. Clinical application and efficacy of silver drug in ophthalmology: a literature review and new formulation of EYE drops with drug silver (I) complex of metronidazole with improved dosage form. Biomedicines 9, 210 (2021).
pubmed: 33669740 pmcid: 7922215
Starek, M., Dąbrowska, M., Chebda, J., Żyro, D. & Ochocki, J. Stability of metronidazole and its complexes with silver(I) salts under various stress conditions. Molecules 26, 3582 (2021).
pubmed: 34208193 pmcid: 8230755
Radko, L., Stypuła-Trębas, S., Posyniak, A., Żyro, D. & Ochocki, J. Silver(I) complexes of the pharmaceutical agents metronidazole and 4-hydroxymethylpyridine: comparison of cytotoxic profile for potential clinical application. Molecules (Basel) 24, 1949 (2019).
Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033 (2009).
Yu, J. et al. Remote loading paclitaxel–doxorubicin prodrug into liposomes for cancer combination therapy. Acta Pharm. Sin. B 10, 1730–1740 (2020).
pubmed: 33088692 pmcid: 7564015
Guo, G., Guo, T. & Chang, X. Effect of CYP3A4 genetic polymorphisms on pharmacokinetics of tinidazole. Journal of Chinese Pharmaceutical Sciences 29, 272–279 (2020).
Sivanesan, S. et al. Pharmacokinetics of the individual major components of polymyxin B and colistin in rats. J. Nat. Prod. 80, 225–229 (2017).
pubmed: 28080060
Rubinstein, M. R. et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 14, 195–206 (2013).
pubmed: 23954158 pmcid: 3770529
Geng, F., Zhang, Y., Lu, Z., Zhang, S. & Pan, Y. Fusobacterium nucleatum caused DNA damage and promoted cell proliferation by the Ku70/p53 pathway in oral cancer cells. DNA Cell Biol. 39, 144–151 (2020).
pubmed: 31765243 pmcid: 6978777
Zhang, S. et al. Fusobacterium nucleatum promotes epithelial-mesenchymal transiton through regulation of the lncRNA MIR4435-2HG/miR-296-5p/Akt2/SNAI1 signaling pathway. FEBS J. 287, 4032–4047 (2020).
pubmed: 31997506 pmcid: 7540502
Park, E. M. et al. Targeting the gut and tumor microbiota in cancer. Nat. Med. 28, 690–703 (2022).
pubmed: 35440726
Smith, M. et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat. Med. 28, 713–723 (2022).
pubmed: 35288695 pmcid: 9434490
Lobionda, S., Sittipo, P., Kwon, H. Y. & Lee, Y. K. The role of gut microbiota in intestinal inflammation with respect to diet and extrinsic stressors. Microorganisms 7, 271 (2019).
Nie, K. et al. Roseburia intestinalis: a beneficial gut organism from the discoveries in genus and species. Front. Cell. Infect. Microbiol. 11, 757718 (2021).
pubmed: 34881193 pmcid: 8647967
Okano, K., Shimoda, T. & Matsumura, Y. Clinicopathologic and immunohistochemical study of early colorectal cancer with liver metastases. J. Gastroenterol. 34, 334–340 (1999).
pubmed: 10433008
Goodwin, T. J., Zhou, Y., Musetti, S. N., Liu, R. & Huang, L. Local and transient gene expression primes the liver to resist cancer metastasis. Sci. Transl. Med. 8, 364ra153 (2016).
pubmed: 27831902 pmcid: 5512420
Han, Y. K. et al. Hypoxia induces immunogenic cell death of cancer cells by enhancing the exposure of cell surface calreticulin in an endoplasmic reticulum stress-dependent manner. Oncol Lett. 18, 6269–6274 (2019).
pubmed: 31788104 pmcid: 6865837
Cao, J. et al. Heat shock protein 70 attenuates hypoxiainduced apoptosis of pulmonary microvascular endothelial cells isolated from neonatal rats. Mol. Med. Rep. 24, 690 (2021).
He, Y., Xiang, Z. & Mobley, H. L. Vaxign: the first web-based vaccine design program for reverse vaccinology and applications for vaccine development. J. Biomed. Biotechnol. 2010, 297505 (2010).
pubmed: 20671958 pmcid: 2910479
Ong, E. et al. Vaxign2: the second generation of the first Web-based vaccine design program using reverse vaccinology and machine learning. Nucleic Acids Res. 49, W671–W678 (2021).
pubmed: 34009334 pmcid: 8218197
Ali Mohammed, M. M., Pettersen, V. K., Nerland, A. H., Wiker, H. G. & Bakken, V. Label-free quantitative proteomic analysis of the oral bacteria Fusobacterium nucleatum and Porphyromonas gingivalis to identify protein features relevant in biofilm formation. Anaerobe 72, 102449 (2021).
pubmed: 34543761
Mohammed, M. M. A., Pettersen, V. K., Nerland, A. H., Wiker, H. G. & Bakken, V. Quantitative proteomic analysis of extracellular matrix extracted from mono- and dual-species biofilms of Fusobacterium nucleatum and Porphyromonas gingivalis. Anaerobe 44, 133–142 (2017).
pubmed: 28285095
Cameron, M. & Williams, H. E. Comparing compressed sequences for faster nucleotide BLAST searches. IEEE/ACM Trans. Comput. Biol. Bioinform. 4, 349–364 (2007).
pubmed: 17666756
Stevens, J., Wiesmüller, K.-H., Walden, P. & Joly, E. Peptide length preferences for rat and mouse MHC class I molecules using random peptide libraries. Eur. J. Immunol. 28, 1272–1279 (1998).
pubmed: 9565367
Gil-Cruz, C. et al. Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy. Science 366, 881–886 (2019).
pubmed: 31727837
Sato, T. et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459, 262–265 (2009).
pubmed: 19329995
LeBlanc, D. J., Lee, L. N. & Abu-Al-Jaibat, A. Molecular, genetic, and functional analysis of the basic replicon of pVA380-1, a plasmid of oral streptococcal origin. Plasmid 28, 130–145 (1992).
pubmed: 1409970
Kennedy, M. J. et al. Rapid blue-light-mediated induction of protein interactions in living cells. Nat. Methods 7, 973–975 (2010).
pubmed: 21037589 pmcid: 3059133
Krienke, C. et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science 371, 145–153 (2021).
pubmed: 33414215
Hu, Z. et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat. Med. 27, 515–525 (2021).
pubmed: 33479501 pmcid: 8273876
Munoz-Price, L. S., Frencken, J. F., Tarima, S. & Bonten, M. Handling time-dependent variables: antibiotics and antibiotic resistance. Clin. Infect. Dis. 62, 1558–1563 (2016).
pubmed: 27025824
Song, W. et al. Trapping of lipopolysaccharide to promote immunotherapy against colorectal cancer and attenuate liver metastasis. Adv. Mater. 30, e1805007 (2018).
pubmed: 30387230 pmcid: 6580426
Song, W. et al. Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. Nat. Commun. 9, 2237 (2018).
pubmed: 29884866 pmcid: 5993831
Hu, M. et al. Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy. Nat. Commun. 10, 2993 (2019).
pubmed: 31278269 pmcid: 6611764
Gmur, R., Wyss, C., Xue, Y., Thurnheer, T. & Guggenheim, B. Gingival crevice microbiota from Chinese patients with gingivitis or necrotizing ulcerative gingivitis. Eur. J. Oral Sci. 112, 33–41 (2004).
pubmed: 14871191
Caporaso, J. G. et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc. Natl Acad. Sci. USA 108, 4516–4522 (2011).
pubmed: 20534432
Mohsen, A., Park, J., Chen, Y. A., Kawashima, H. & Mizuguchi, K. Impact of quality trimming on the efficiency of reads joining and diversity analysis of Illumina paired-end reads in the context of QIIME1 and QIIME2 microbiome analysis frameworks. BMC Bioinformatics 20, 581 (2019).
pubmed: 31730472 pmcid: 6858638
Caporaso, J. G. et al. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 7, 335–336 (2010).
pubmed: 20383131 pmcid: 3156573
Callahan, B. J. et al. DADA2: high-resolution sample inference from Illumina amplicon data. Nat. Methods 13, 581–583 (2016).
pubmed: 27214047 pmcid: 4927377
DeSantis, T. Z. et al. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl. Environ. Microbiol. 72, 5069–5072 (2006).
pubmed: 16820507 pmcid: 1489311
Quast, C. et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 41, D590–D596 (2013).
pubmed: 23193283
Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol. Biol. Evol. 30, 772–780 (2013).
pubmed: 23329690 pmcid: 3603318
Price, M. N., Dehal, P. S. & Arkin, A. P. FastTree 2—approximately maximum-likelihood trees for large alignments. PLoS ONE 5, e9490 (2010).
pubmed: 20224823 pmcid: 2835736
Segata, N. et al. Metagenomic biomarker discovery and explanation. Genome Biol. 12, R60 (2011).
pubmed: 21702898 pmcid: 3218848
Sun, Y. et al. Killing tumor-associated bacteria with a liposomal antibiotic generates microbial neoantigens that induce anti-tumor immune responses. (2023). https://zenodo.org/record/8200515

Auteurs

Menglin Wang (M)

Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.

Benoit Rousseau (B)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Kunyu Qiu (K)

Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.

Guannan Huang (G)

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Department of Genetics, University of North Carolina, Chapel Hill, NC, USA.
Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA.

Yu Zhang (Y)

Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.

Hang Su (H)

Department of Bioinformatics and Computational Biology, University of North Carolina, Chapel Hill, NC, USA.

Christine Le Bihan-Benjamin (C)

Health Data and Assessment Department, Data Science and Assessment Division, French National Cancer Institute, Boulogne-Billancourt, France.

Ines Khati (I)

Health Data and Assessment Department, Data Science and Assessment Division, French National Cancer Institute, Boulogne-Billancourt, France.

Oliver Artz (O)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Michael B Foote (MB)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Yung-Yi Cheng (YY)

Natural Products Research Laboratories, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.

Kuo-Hsiung Lee (KH)

Natural Products Research Laboratories, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
Chinese Medicine Research and Development Center, China Medical University and Hospital, Taichung, Taiwan.

Michael Z Miao (MZ)

Curriculum in Oral and Craniofacial Biomedicine, Division of Oral and Craniofacial Health Sciences, Adams School of Dentistry, University of North Carolina, Chapel Hill, NC, USA.
Thurston Arthritis Research Center, Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, USA.

Yue Sun (Y)

Department of Radiology and Biomedical Research Imaging Center, University of North Carolina, Chapel Hill, NC, USA.

Philippe-Jean Bousquet (PJ)

Health Survey, Data Science and Assessment Division, French National Cancer Institute, Boulogne Billancourt, France.

Marc Hilmi (M)

GERCOR Group, Paris, France.
Medical Oncology Department, Curie Institute, Saint Cloud, France.

Elise Dumas (E)

Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.
INSERM, U900, Paris, France.
MINES ParisTech, PSL Research University, CBIO-Centre for Computational Biology, Paris, France.

Anne-Sophie Hamy (AS)

Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.
Department of Medical Oncology, Centre René Hughenin, Saint Cloud, France.

Fabien Reyal (F)

Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.
Department of Surgery, Institut Jean Godinot, Reims, France.
Department of Surgical Oncology, Institut Curie, University of Paris, Paris, France.

Lin Lin (L)

BMTCT Program, Division of Hematology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.

Paul M Armistead (PM)

BMTCT Program, Division of Hematology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Department of Internal Medicine, University of North Carolina, Chapel Hill, NC, USA.

Wantong Song (W)

Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, China.
Jilin Biomedical Polymers Engineering Laboratory, Changchun, China.

Ava Vargason (A)

Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.

Janelle C Arthur (JC)

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA.
Center for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, NC, USA.

Yun Liu (Y)

Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.

Jianfeng Guo (J)

Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.

Xuefei Zhou (X)

Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.

Juliane Nguyen (J)

Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.

Yongqun He (Y)

Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.
Unit for Laboratory Animal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI, USA.

Jenny P-Y Ting (JP)

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Department of Genetics, University of North Carolina, Chapel Hill, NC, USA.
Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA.
Division of Craniofacial and Surgical Care, School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Aaron C Anselmo (AC)

Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.

Leaf Huang (L)

Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA. leafh@email.unc.edu.

Classifications MeSH